![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » INTELLIPHARMACEUTICS AND PAR PHARMACEUTICAL AGREE TO CONTROLLED RELEASE GENERIC DRUG DEVELOPMENT
INTELLIPHARMACEUTICS AND PAR PHARMACEUTICAL AGREE TO CONTROLLED RELEASE GENERIC DRUG DEVELOPMENT
November 30, 2005
IntelliPharmaCeutics Corp., a Canadian specialty pharmaceutical company, the operating affiliate of IntelliPharmaCeutics Ltd., (Delaware), is pleased to announce that it has entered into an agreement with Par Pharmaceutical Companies, Inc. (NYSE: PRX) for the development of a generic, controlled release drug product for the United States market. Financial terms of the agreement were not disclosed.
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051130005117&newsLang=en)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct